France: a groundbreaking report takes stock of medical cannabis

As France prepares to take a new step towards legalizing medical cannabis, a groundbreaking report, the fruit of several months' work, has just been published to offer a detailed insight into the future French market.

Co-directed by Newsweed and consulting firm Augur Associates, this report entitled « Overview of the medical cannabis industry in France »A comprehensive overview of French specificities, regulatory developments and future business opportunities.

An evolving context

For several years now, the subject of medical cannabis has been making gradual progress in France, notably through experiments supervised by the ANSM. But many questions remain unanswered:

• What will the future permanent legal framework look like?
• What exactly will be the role of the pharmaceutical industry?
• What specific constraints will the French healthcare system impose?
• How will private players fit into this market?

This report provides concrete answers to these questions, This is based on an in-depth regulatory watch, feedback from various European players and a strategic analysis of the forces at play.

A tool for industry players

The report is aimed at a wide audience:

• Medical cannabis and pharmaceutical companies
• Investors and specialized funds
• Healthcare professionals
• Institutional players and political decision-makers
• Journalists and analysts
• Curious about future developments

His ambition is clear: provide a realistic, well-argued and operational overview of the French medical cannabis market, in a European context where each country adopts a specific model.

Available on free access

The report is available free of charge in English and French.

Download the report here : https://www.augur.associates/rapports

A decisive turning point

If France adopts a structured, sustainable medical cannabis model in the coming months, the stakes will be high, for patients, healthcare professionals and the entire industry.

The aim of this report is to document the foundations of the French medical cannabis industry and to support all stakeholders in this crucial market-building phase.